In a landmark move that promises to reshape the biosolutions landscape, Novozymes and Chr. Hansen have successfully merged to form Novonesis, heralding a new chapter in sustainable business practices and environmental stewardship. With a workforce of 10,000 employees and a presence in over 30 industries, Novonesis is poised to become a pivotal player in promoting healthier lifestyles and more sustainable business practices across the globe.
The journey to this transformative merger began on December 12, 2022, when the two companies announced their intention to join forces. Following rigorous regulatory scrutiny, the merger has now been finalized, marking a significant milestone in the industry. The new entity, headquartered in Copenhagen, Denmark, is a testament to the companies’ shared vision of leveraging the wonders of biology to forge a better future.
Ester Baiget, the newly appointed President and CEO of Novonesis, expressed her enthusiasm for the merger, emphasizing the combined strengths of the two companies in leading the next wave of biosolutions innovation. Under her leadership, Novonesis aims to revolutionize the production and consumption patterns of industries worldwide, harnessing the potential of biosolutions to address some of the most pressing challenges facing our planet.
Cees de Jong, Chairman of Novonesis, echoed Baiget’s sentiments, highlighting the century-long legacy of innovation and expertise that the combined entity brings to the table. He stressed the company’s commitment to being a growth partner for customers, a value creator for shareholders, and a force for positive change in society and the environment.
With a projected annual revenue of approximately EUR 3.7 billion, Novonesis is set to focus on two core areas: enhancing human health and food quality, and promoting environmentally friendly practices to achieve climate neutrality. This dual focus reflects the company’s commitment to balancing economic success with ecological sustainability.
The choice of the name ‘Novonesis’ pays homage to the company’s roots in science and innovation, drawing inspiration from the Greek word ‘genesis’ and the Latin ‘novo’ to signify a new beginning in the field of biosolutions. This symbolic naming underscores the company’s dedication to pioneering advances in the industry while honoring the scientific heritage that underpins its work.
As Novonesis moves forward, it has outlined ambitious financial and sustainability goals, including significant revenue growth, improved profitability, and substantial reductions in carbon emissions. The company also aims to achieve a more balanced gender representation in its professional and senior management ranks by 2030.
In the coming months, Novonesis will provide further details on its financial outlook and operational strategies, culminating in a Capital Markets Day in London on June 18, 2024. This event will offer insights into the company’s integration process, synergies, and the innovative technology platform that will drive its future growth.
As Novonesis embarks on this exciting journey, the global community watches with anticipation, eager to see how this new powerhouse will leverage its collective expertise to foster a healthier, more sustainable world.
